Healthcare | May 05, 2026
OBESITAS 2026 concludes with focus on India’s rising obesity burden
The conference brought together over 500 doctors and 150 nutritionists to discuss emerging obesity-related challenges
The conference brought together over 500 doctors and 150 nutritionists to discuss emerging obesity-related challenges
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
The ISG assessment highlights Indegene’s deep domain expertise, proprietary technology stack, and expanding use of AI and GenAI to drive more integrated, data-led commercial execution across the life sciences value chain
The company secured new accounts, including ACCESS-PVI trial sites, and aims to strengthen global commercialization efforts
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing
The company’s Growth Portfolio delivered $6.2 billion in revenue
Lifts full-year outlook as obesity drug boom accelerates
Stroke is the second-leading cause of death and the third-leading cause of disability worldwide
The renewal covers two versions of the IQOS device and three HEETS tobacco variants
Subscribe To Our Newsletter & Stay Updated
